 |
|
|
|
|
PORTFOLIO NEWS
CASIGEN, February 2012
Casigen Pharma Ltd, a new portfolio company of Ventac Partners incorporated in Hong Kong as a spin off
from the Guangzhou Institute of Biomedicine and Health, is granted a worldwide exclusive license to develop novel therapeutic compounds for metabolic and autoimmune
disease indications.
AVEXXIN, January, 2012
Avexxin is closing series A financing round enabling the company to take its lead compound forward through clinical trial phase I/IIa.
Open PRESS RELEASE.
ZESTAGEN, October, 2011
Ventac Partners is co-founder of Zestagen S.A. , a cancer company spun out from the Hellenic Pasteur Institute. The company is exploiting a novel discovery of a therapeutic, biological agent targeting HSP90. Partner, Martin Austin becomes the Chairman of the Board. The company secures seed funding up to USD 1.4 million.
REGENESANCE, October, 2011
Regenesance receives innovation credit from Dutch Government. The Dutch Ministry of Economic Affairs and Innovation (Agentschap, NL) awarded a substantial credit to Regenesance for the development of new compounds to treat Multiple Sclerosis. The credit will provide up to 35% of the costs advancing a lead compound through clinical phase IIa. Total support could approach USD 5 million.
Open PRESS RELEASE.
REGENESANCE, November, 2010
Regenesance receives a seed-stage investment from Life Sciences Fund Amsterdam of USD 900,000.
Open PRESS RELEASE.
REGENESANCE, August, 2010
Regenesance B.V. opens Boston office to assist with drug development strategy in USA.
AVEXXIN, January, 2010
Avexxin closes Series A financing round of USD 2.8 million enabling the company to take its lead compound forward through clinical trial phase I/IIa.
REGENESANCE, November, 2009
Ventac Partners is co-founder of Regenesance B.V., a specialty pharma company dedicated to developing treatments that reduce nerve damage accompanying disease or injury. Regenesance builds on the discovery of a novel therapeutic intervention point discovered at Academic Medical Center in Amsterdam . Partner, Robert L. Buchanan appointed the CEO.
AVEXXIN, April, 2009
Avexxin is granted USD 1.4 million by the Norwegian Research Council to expand its activities in chemistry and drug discovery targeting rheumatoid arthritis and other chronic inflammatory disorders. The company enters into collaboration with University of Athens , University of California San Diego , University of Bern and the Norwegian University of Science and Technology.
AVEXXIN, August, 2007
Avexxin enters into collaboration with University of Bern regarding investigation of Avexxin compounds in glomerular disease.
EXIQON, May, 2007
Exiqon lists on Nasdac OMX, Copenhagen Stock Exchange.
AVEXXIN, December, 2006
The Norwegian Research Council grants Avexxin financial support of USD 1.7M to expand its activities in chemistry and drug discovery in new indications in chronic inflammatory disorders.
AVEXXIN, February, 2006
The Norwegian Research Council grants Avexxin financial support of USD 1.4M to advance its psoriasis project.
AVEXXIN, May, 2005
Ventac Partners is co-founder of Avexxin AS , a Norwegian company focused on development and commercializing novel small molecules therapeutics for patients with chronic inflammatory disorders. The company exploits a novel therapeutic intervention point discovered at the Norwegian University of Science and Technologies and is a spin off from Leiv Eirikssen Nyskaping AS.
